Abstract
The aim of our work was to study the relationship of tumor necrotic factor and receptor 1 to tumor necrotic factor in physiological uterine pregnancy in the first trimester and in pregnant women with ectopic pregnancy who received different doses of cytostatic methotrexate for its treatment.Methods and materialsWe analyzed the results of special research methods and examined 30 pregnant women with advanced uterine pregnancy in the first trimester and 40 pregnant women with advanced ectopic pregnancy treated with methotrexate, depending on the dose of methotrexate patients were divided into 2 groups of 20 women. The first group (M1) received 75-100 mg (based on kg of weight) of methotrexate intramuscularly, and the second group (M2) received methotrexate at a dose of 75-100 mg twice after 7 days.Research resultsIn healthy pregnant women with physiological pregnancy for 3-4 weeks, the level of TNF-α in blood neutrophils was within 2.02 ± 0.16 ng / ml and in pregnant women with ectopic pregnancy - 2.64 ± 0.19 ng / ml. In the M1 group, TNF-α level was slightly higher (5.49 ± 0.24 ng / ml, p <0.01) than in the group of women with ectopic pregnancy before treatment (2.64 ± 0.19) ng / ml, whereas in the methotrexate (M2) reintroduction group this indicator increased almost 4 times (10.30 ± 0.26 ng / ml) and in the M1 group almost 2.3 times (5.49 ± 0.24) ng / ml). The number of activated TNF-R1 neutrophils in the M1 group was (11.16 ± 0.30) ng / ml, versus (16.26 ± 0.43) ng / ml in the M2 group (p <0.05).ConclusionsNeutrophil blood cells are sensitive cells of the body to study the assessment of the depth of action of cytostatic at the body level as a whole.Indicators of tumor necrotic factor and receptor 1 tumor necrotic factor can be used as a marker of activity of cytotoxic action of different doses of methotrexate for the treatment of progressing ectopic pregnancy.